P1/2, N=39, Active, not recruiting, BioCardia, Inc. | Enrolling by invitation --> Active, not recruiting | Trial completion date: Jul 2025 --> Dec 2027 | Trial primary completion date: Jul 2025 --> Dec 2026

P2, N=150, Recruiting, St. Vincent's Hospital, Sydney | Not yet recruiting --> Recruiting

P1, N=6, Recruiting, GEn1E Lifesciences | Not yet recruiting --> Recruiting

For instance, L-citrulline can be cleaved by cathepsin B, while D-citrulline is not...Using this novel approach, citrulline-containing DL's, compounds A-D, were all baseline resolved with a single set of TWIMS parameters. This work underscores the critical role of high-resolution SLIM-IM-MS in resolving subtle structural differences in chiral ADC components, providing essential insights into their development and quality control.

A diagnosis of sarcoid dactylitis was made and treatment commenced with a reducing course of prednisolone 40 mg daily, along with hydroxychloroquine 200 mg twice daily...The radiological findings can therefore aid diagnosis. Our case highlights the rare initial presentation of dactylitis as a manifestation of paraneoplastic sarcoid.

P2, N=48, Recruiting, The First Affiliated Hospital with Nanjing Medical University

P1, N=20, Recruiting, Rutgers, The State University of New Jersey | Active, not recruiting --> Recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

Molecular docking brilliantly illuminated the mechanism behind this divergence: the potent cytotoxicity of C. viminale is driven by its principal alkaloids, Protopine and Berberine, which showed high-affinity binding to the ATP-binding site of EGFR, a key driver of cancer proliferation. DHFR, conversely, was identified as a common molecular target for potent binders from both plants (Evodiamine, Piperine, Chlorogenic acid), providing a unifying mechanism for their shared antimicrobial properties.

It represents a promising therapeutic approach to counteract age-related immune dysfunction and inflammation, potentially by slowing the aging process. Further research is needed to validate its long-term efficacy and safety in geriatrics.

P1/2, N=160, Active, not recruiting, Enlivex Therapeutics Ltd. | Trial completion date: Feb 2026 --> May 2026 | Trial primary completion date: Sep 2025 --> Mar 2026

P=N/A, N=270, Not yet recruiting, West China Hospital

P1, N=12, Recruiting, Sun Yat-sen University